dacarbazine and Intestinal Neoplasms

dacarbazine has been researched along with Intestinal Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (25.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Dureja, S; Gupta, SK; Kumar, S; Kumari, J; Malasani, V; Pant, V; Sen, I; Thakral, P; Un, P	1
Costa, FP; Gumz, B; Pasche, B	1
Claringbold, PG; Kesavan, M; Turner, JH	1
Goldman, SL; Pollak, EW; Wolfman, EF	1

Reviews

1 review(s) available for dacarbazine and Intestinal Neoplasms

Article	Year
Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide	2012

Article

Year

Selecting patients for cytotoxic therapies in gastroenteropancreatic neuroendocrine tumours.

Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6

Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Proliferation; Dacarbazine; Deoxycytidine; Fluorouracil; Humans; Intestinal Neoplasms; Neoplasm Grading; Neoplasm Staging; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Prognosis; Stomach Neoplasms; Streptozocin; Temozolomide

2012

Trials

1 trial(s) available for dacarbazine and Intestinal Neoplasms

Article	Year
Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up. Neuroendocrinology, 2014, Volume: 99, Issue:2 Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome	2014

Article

Year

Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.

Neuroendocrinology, 2014, Volume: 99, Issue:2

Topics: Adult; Aged; Anemia; Antineoplastic Agents; Blood Platelets; Capecitabine; Dacarbazine; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Incidence; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Neutrophils; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stomach Neoplasms; Temozolomide; Thrombocytopenia; Treatment Outcome

2014

Other Studies

2 other study(ies) available for dacarbazine and Intestinal Neoplasms

Article	Year
Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM). The British journal of radiology, 2018, Volume: 91, Issue:1091 Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution	2018
Massive upper gastrointestinal bleeding during chemotherapy for malignant melanoma. The American surgeon, 1977, Volume: 43, Issue:11 Topics: Dacarbazine; Gastrointestinal Hemorrhage; Humans; Intestinal Neoplasms; Jejunum; Male; Melanoma; Middle Aged; Stomach Neoplasms; Triazenes	1977

Article

Year

Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).

The British journal of radiology, 2018, Volume: 91, Issue:1091

Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Capecitabine; Case-Control Studies; Chemoradiotherapy; Dacarbazine; Drug Administration Schedule; Female; Humans; Intestinal Neoplasms; Liver; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Spleen; Stomach Neoplasms; Temozolomide; Tissue Distribution

2018

Massive upper gastrointestinal bleeding during chemotherapy for malignant melanoma.

The American surgeon, 1977, Volume: 43, Issue:11

Topics: Dacarbazine; Gastrointestinal Hemorrhage; Humans; Intestinal Neoplasms; Jejunum; Male; Melanoma; Middle Aged; Stomach Neoplasms; Triazenes

1977